|
5α-reductase inhibitors (5-ARIs) are a class of drugs with antiandrogen effects, used primarily in the treatment of benign prostatic hyperplasia (BPH) and androgenic alopecia. These agents inhibit the enzyme 5α-reductase, which is involved in the metabolic transformations of a variety of endogenous steroids. 5α-reductase inhibition is most known for preventing conversion of testosterone, the major androgen sex hormone, to the more potent dihydrotestosterone (DHT), in androgen-associated disorders. == Medical use == 5-ARIs are clinically used in the treatment of conditions that are exacerbated by DHT:〔Rossi S (Ed.) (2004). ''Australian Medicines Handbook 2004''. Adelaide: Australian Medicines Handbook. ISBN 0-9578521-4-2〕 * Mild-to-moderate benign prostatic hyperplasia and lower urinary tract symptoms * Androgenic alopecia in both men and women They have also been explored in the treatment and prevention of prostate cancer. However, their use for this indication is controversial, as some authors have expressed concern that they may inadvertently lead to development of more aggressive tumor variants. 5-ARIs are also sometimes employed as supplementary antiandrogens in hormone replacement therapy for trans women. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「5-alpha-reductase inhibitor」の詳細全文を読む スポンサード リンク
|